Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
alt text
sign up
Synairgen Ltd
Company Name:Synairgen Ltd Minimum fundraise:£0.00* High Share Price Bid:£0.00
Business Sector:Pharmaceuticals, healthcare and biotechnology Total Funds Bid to Date:- Low Share Price Bid:£0.00
Auction period:02 Sep 2025 - 30 Sep 2025 Indicative Share Price:0.00 Average Share Price Bid:£0.00**
Company Details Below
*The company will accept oversubscription.
**In the event of significant oversubscription, shares will be allocated to bids at the average price and above.
NOTE: ASSET MATCH HAS NEGOTIATED AN “ASSET MATCH INVESTOR BONUS” FOR INVESTORS IN THIS TRANSACTION. SEE THE “OVERVIEW” SECTION BELOW FOR DETAILS.

Need help?
+44 (0) 207 248 2788

back

Synairgen Ltd

Synairgen Ltd has appointed Asset Match to provide a secondary trading facility in the Company's Ordinary Shares.

The first auction is currently set to run in September 2025. The planned opening date will be the 2nd September with the auction set to close on Tuesday 30th September at 3pm.

Please be mindful that the above stated dates may still be subject to change.

An order form will be made available on this page once the auction is live and an Orderbook will be visible once any orders have been received. 

If you would like to receive further information and subsequent auction details then please email synairgen@assetmatch.com or add Synairgen to your watchlist.

Please direct any queries to synairgen@assetmatch.com or Tel. 020 7248 2788

Interested in Synairgen Ltd?
Register or log in to participate, create a watchlist, or set reminder

Register Log in

Company info

Synairgen is a UK-based respiratory company focused on the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

SNG001 has been tested in several clinical studies in both out-patient and hospital settings and was found to boost lung antiviral responses, accelerate viral clearance from the lungs, be well tolerated and show potential for clinical benefit in patients with various respiratory infections.

www.synairgen.com

Auction Details

The Ordinary Shares of Synairgen Ltd were admitted to trading on Asset Match on 9 April 2025 at a price of 0.95 pence per share, being the last closing price on AIM.

Auctions are to be confirmed.

The tick size for this company is 0.01 pence per share.

Participants can send instructions by completing the online order form below. Further instructions on how to participate and the related processes can be found by clicking on the "Auction instructions" section below.

Order form: Coming soon. 

Auction instructions

Placing an order

  • You can place an order by filling in the order form on the Synairgen page indicating:
    • the number of shares you wish to buy or sell
    • the maximum / minimum price in pence at which you wish to buy/sell (tick size of 0.01p)
  • Once approved and if your order is valid, you will receive a confirmation email and the order will be reflected in a near real-time order book

Amend / withdraw an order

  • You can amend an order by filling in the order form again on the Synairgen page indicating your amendment
  • You can amend / withdraw your order at any point
  • Once approved and if your order is valid, you will receive a confirmation email and the amended / withdrawn order will be reflected in a real-time order book

Auction Close

  • Participants will be contacted via email to confirm the trade (successful and unsuccessful)
  • If an order is unsuccessful, orders can be re-entered into the next auction
  • If an order is successful, Asset Match informs and instructs the transacting parties by email to complete settlement off-market
  • Settlement will require the setup of an Escrow account
  • A successful seller will be repsonsbile for the completion of relevant transfer documentation and provision of original share ceritifcate 
  • All funds (including commission and stamp duty for the buyer) will be held in Escrow until share transfer is complete. Funds will only to be released to seller once confirmed by MUFG Corporate Markets (Registrars)

Please note that the manual transfer of shares involves the confirmation and payment of Stamp Duty to HMRC, this process can take circa 6-8 weeks to be completed before the tranfer is approved and funds can be released from Escrow. 

When buying and selling shares, please note that the Asset Match levy of 3% applies, with a minimum charge of £20 per trade (additional fees may apply).  Please see Internal Market Rules for full details.

Please direct any enquiries to Asset Match on Tel: (0)20 7248 2788 or synairgen@assetmatch.com

Key People

Mark

Mark Parry Billings Chairman

Dr. Mark Parry-Billings joined Synairgen in October 2024 as Chairman of the Board of Directors. Mark is an accomplished international biotech and pharmaceutical executive with a successful track record of more than 30 years in leadership and senior R&D roles. Most recently, he served as Global Head of Drug Development at Chiesi. Prior to this, he served as CEO of Topigen Pharmaceuticals until its acquisition by Pharmaxis in 2010. Mark has deep expertise in respiratory therapeutics and drug delivery to the lungs, having led multiple novel assets from early stage through clinical development to market approval, with a primary focus on inhaled drug delivery.
   
Richard

Richard Marsden Chief Executive Officer and Executive Director

Richard Marsden joined Synairgen in a consulting role as General Manager in November 2003, was appointed to the Board as Managing Director in June 2004 and was appointed Chief Executive Officer in September 2009. Between 1998 and 2003 he worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited.
   
Joseph

Joseph Colliver Chief Financial Officer, Executive Director

An experienced Chief Financial Officer, Joseph is a Fellow Chartered Accountant with extensive listed company, finance, commercial and consulting experience. Most recently, he has held positions as executive and non-executive directors of listed early-stage life sciences companies, where Joseph led financial reporting, M&A, strategy, and regulatory / corporate governance. Prior to this, Joseph spent ten years in senior leadership roles in the Kantar division of WPP PLC, including CFO at Kantar Futures, and Global Commercial Director of TNS, a multi-billion-dollar global market research agency. Joseph qualified as a chartered Accountant in the audit practice of Mazars LLP.
   
Martin

Martin Murphy Non-Executive Director

Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.
   
John

John Bradshaw Non-Executive Director

Mr Bradshaw is a Chartered Accountant with more than 30 years post-qualification experience working at Board level in UK listed companies, venture capital backed companies and partnerships including Chair of Audit Committee for two AIM listed companies and Chief Financial Officer of Syncona Investment Management Limited, the investment manager of Syncona Limited, a FTSE250 healthcare investment company.